Press Releases Latest Dec 01, 2022 Theratechnologies Announces Update from Ongoing TH1902 Study Press Releases Year None2022202120202019201820172016201520142013 May 31, 2021 Theratechnologies Hires Vice President, Human Resources May 20, 2021 Theratechnologies Announces Results From Two Posters Presented at ACTHIV 2021 Annual Meeting Highlighting Positive Patient Experience With Trogarzo® May 18, 2021 Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021 May 13, 2021 Announcements in Conjunction With Theratechnologies Annual Meeting Apr 14, 2021 Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights Apr 12, 2021 Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference Apr 01, 2021 Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021 Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors First page « Previous page ‹ … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page › Last page » Displaying 51 - 60 of 297
May 20, 2021 Theratechnologies Announces Results From Two Posters Presented at ACTHIV 2021 Annual Meeting Highlighting Positive Patient Experience With Trogarzo®
May 18, 2021 Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021
Apr 14, 2021 Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types
Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets
Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
